Authors should submit their manuscripts online. Electronic submission substantially reduces the editorial processing and reviewing times and shortens overall publication times. Please log in directly at:http://www.editorialmanager.com/mmmo and upload all of your manuscript files following the instructions.
A copy of the certification form included in each issue must be submitted with the manuscript. The editorial board decides whether to accept or reject submitted papers in consultation with at least two referees.
When a manuscript is submitted, authors must disclose any financial relationships they have with business enterprises or for-profit corporate organizations (hereafter referred to as 'Commercial Entities') regarding the subjects or materials treated in the research, if the amount exceeds the criteria
1) Position on the advisory board or board of directors at one or more Commercial Entity, if the compensation from one Commercial Entity exceeds ￥1,000,000 per year.
2) Equity ownership, if the profit from one Commercial Entity exceeds ￥1,000,000 per year.
3) Patent royalties from Commercial Entities, if the royalty fee from one Commercial Entity exceeds ￥1,000,000 per year.
4) Honoraria for speaking paid by one Commercial Entity, if the amount exceeds ￥500,000 per year.
5) Remuneration for writing paid by one Commercial Entity, if the amount exceeds ￥500,000 per year.
6) Research grants provided by one Commercial Entity, if the amount exceeds ￥1,000,000 per year.
7) Belonging to endowed departments provided by Commercial Entities.
If there is no such COI, the authors should make a statement as follows: The authors declare that they have no confl icts of interest.
These COI-related statements will appear after the Acknowledgments.
If materials used in the study are from patients at clinics, it should be stated in the text that the study has been reviewed and approved by the ethics committee for clinical research in the research institutes where the study has been performed, accompanied by the number for the approval.
Medical Molecular Morphology welcomes articles on basic or clinical research in the fields of cell biology, molecular biology, and medical, veterinary, and dental sciences using techniques for structural research such as electron microscopy, confocal laserscanning microscopes, enzyme histochemistry, immunohistochemistry, X-ray microanalysis, in-situ hybridization, and computer-based 3D reconstruction.
Articles may be in the form of original papers, reviews, case reports, or letters. The maximum length for each type of article is 10, 15, 5, and 1 printed pages, respectively.
Complete manuscripts, including tables and figures, must be supplied in MS Word format; the abstract, text, references, tables and figure legends must be typed double-space with wide margins. A complete list of submitted materials must accompany each manuscript. Incomplete or improperly prepared manuscripts will be returned to the authors without review.
A separate title page should be provided. The abstract, text, acknowledgments, references, tables, legends and figures should begin on separate pages and follow in that order. Standard abbreviations and units should be used. Abbreviations should be defined the first time they are mentioned, and their use in the title and abstract should be avoided.
The generic names of drugs and chemicals should be used.
All manuscripts must be written in English.
Authors who are not fl uent in English must seek the assistance of a colleague who is a native English speaker and is familiar with the field of work. Manuscripts that have been extensively modified in the editorial process will be returned to the authors for retyping.
For vector graphics figures, the preferred format is EPS; for halftones, please use TIFF format. MS Office files are also acceptable.
All files should be uploaded in the online submission system.
Titles should be brief, specific, and informative.
Include the full names of authors; academic affiliation; address to which proofs are to be sent, including a fax number, telephone number, and e-mail address; and 5–7 key words or phrases for indexing. Key words in the title should be included.
Number references consecutively in the order cited in the text, not alphabetically.
The accuracy of reference data is the authors’ responsibility. Personal communications and unpublished data should not be included in the reference list but may be cited in parentheses in the text. If such a citation is from someone other than the authors, a letter should be submitted in which the direct quotation is given with the signature of its author. In the reference list, provide
inclusive page numbers for all references and give the names of all authors (the use of “et al.” is unacceptable). Journal titles should be abbreviated according to the ISSN List of Title Word Abbreviations (http://www.issn.org/services/online-services/access-to-the-ltwa/). Reference citations in the text should be identified by numbers in square brackets, e.g., Abdelatif et al. , Matsuda and Ichida , and Morson .
1. Abdelatif OMA, Khankhanian NK, Crosby JH, Chamberlain CR Jr, Seigler MM, Tom GD (1989) Malignant fibrous istiocytoma and malignant melanoma: the role fimmunohistochemistry and electron microscopy in differential diagnosis. Mod Pathol 2:477–485
2. Matsuda Y, Ichida T (2006) p16 and p27 are functionally correlated during the progress of hepatocarcinogenesis. Med Mol Morphol 39:169–175
3. Morson PC (1975) Pathology of ulcerative colitis. In: Kirsner JB, Shorter RG (eds) Inflammatory bowel disease. Lea and Febiger, Philadelphia, pp 167–181
In addition to the normal publication process (whereby an article is submitted to the journal and access to that article is granted to customers who have purchased a subscription), Springer provides an alternative publishing option: Springer Open Choice. A Springer Open Choice article receives all the benefits of a regular subscription-based article, but in addition is made available publicly through Springer’s online platform SpringerLink.
Springer Open Choice [http://springer.com/openchoice]
Authors will be asked to transfer copyright of the article to the Japanese Society for Clinical Molecular Morphology (or grant the Japanese Society for Clinical Molecular Morphology exclusive publication and dissemination rights). This will ensure the widest possible protection and dissemination of information under copyright laws.
The purpose of the proof is to check for typesetting or conversion errors and the completeness and accuracy of the text, tables and figures. Substantial changes in content, e.g., new results, corrected values, title and authorship, are not allowed without the approval of the Editor.
After online publication, further changes can only be made in the form of an Erratum, which will be hyperlinked to the article.
The article will be published online after receipt of the corrected proofs. This is the official first publication citable with the DOI. After release of the printed version, the paper can also be cited by issue and page numbers.